sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. sirolimus must be used within a narrow therapeutic window. due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. t...

background acute rejection remains a major problem in renal transplantation and represents one of the most important causes of chronic allograft dysfunction and late graft loss. daclizumab is a genetically engineered human igg1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor, and may thus reduce the risk of rejection after renal transplantation. objectiv...